NOVO NORDISK is launching an online pharmacy that follows the footsteps of ELI LILLY and allows people to buy weight loss drugs directly from the company. Despite the advantages of the first rival of the competitors, it is the latest sign of LILLY’s strong position in a favorable obesity race. Denmark’s pharmaceutical company has published the creation of Novocare, a consumer online online pharmacy. This proposal is suitable for those with valid Wegovy prescriptions that pay cash and have no health insurance or exclude the scope of obesity drugs. Monthly prices are the same for all dose Wegovy, which starts from 0.25 milligrams and up to 2.4 milligrams. The patient usually starts at low doses, starts work over time, and then takes “maintenance” dose to maintain weight loss. Wegovy’s standard list price is $ 1,349 a month, but the company says that most people with insurance don’t pay so much. The announcement comes two weeks after two weeks of saying that on Wednesday that on Wednesday, the US drug regulatory agency said that the lack of WEGOVY and sister drugs Ozempic ended after a crunch of the sister drug, which was used to treat type 2 diabetes. Once, wegovy and ozempic share the active ingredients called Semaglutide. The lack of resolution was a blow to the so -called complex pharmacy, so it was possible to provide a cheaper copycat version of Semaglutide. NOVO currently uses consumer products to rush pressure to like complexes such as HIMS & HERS. NOVOCARE, a big picture, is also taking out the page to meet the strong demand for obesity pharmaceuticals in the playbook of ELI LILLY. In August, LILLY began to provide a discounted Zepbound and blockbuster obesity for valid prescription patients through Lillydirect in August. Last week, drug producers based on Indianapolis lowered the price of the two starter doses available in LillyDirect and made more drugs through the service. In January 2024, the company first started Lillydirect in January 2024 as a method of connecting patients to remote health providers who can use weight loss drugs, including Zepbound. Lilly’s platform also provides prescription delivery. The Zepbound version provided through LillyDirect is provided with a single dose vial, a relatively new option. The drug has historically been delivered through the Autoinjector pen, which has been a major bottleneck that begins to supply. Zepbound’s list price is approximately $ 1,086 a month, but the patient pays depends on insurance. NOVO increases its competitiveness in major GLP-1 rival Lilly in participating in consumer games. But as Wednesday’s stocks move, the market is not really worried. NOVO’s share price increased by about 4%, but LILLY also increased almost 1%. In other words, it doesn’t mean bad news for Lilly because it’s good news for Novo. This is only additional evidence that Novo is holding LILLY in some areas, even though he struck the US market a few years before Lilly’s proposal began in 2017 and 2021, respectively. Lilly’s Mounjaro for Type 2 Diabetes came out in 2022 and in late 2023, Zepbound was about obesity. Both drugs share an active ingredient called Tirzepatide and are injections per week. The GLP-1 craze began in 2022 with the introduction of Ozempic’s weight loss in 2022 thanks to social media. According to a recent note by Bernstein analyst, the recent trend of prescriptions has been advantageous for Zepbound and suggests that the US market share is getting closer to WEGOVY. Zepbound produces an average weight loss than WEGOVY, a research that compares the two drugs found in December. As a large company, LILLY was also able to make more investment in manufacturing ability to help meet the rapid growth demand for pharmaceuticals. Zepbound came from the list of tribes of the Food Pharmacy in December. Looking at the weight loss pipeline of the two companies, LILLY is currently stronger after NOVO is frustrated after the next generation of drugs known as CAGRIEMA in December missed expectations. NOVO’s stock is still about 12%in trading before the data launch. ZEPBOUND’s noisy four -quarter results made it sour until 2025, and LILLY’s stocks rose more than 20% over the same period. Certainly, Lilly’s pipeline has big obstacles as the later test results for the oral GLP-1 or Pogle Glitron are released in the next few months. The first test readings are expected in May and look at the benefits of drugs in type 2 diabetes patients and examine the second readings focused on obesity at the end of the year. Release is expected to be very expected because it is easier to manufacture than injectable versions and can be used as part of the maintenance system, which is considered important in the weight market in the obesity market. Conclusion Lilly remains in the GLP-1 race, even if Novo Nordisk takes better competition in the same region as a pharmacy. The demand for this class is still powerful, and Lilly can run well to expand the capacity and expand access to more patients. The recent adjustment of LillyDirect’s cash payment options is suitable for the latter, just like a partnership with RO, which was announced in December. On the pipeline front, LILLY executives tried to manage investors’ expectations and did not set a high lawyer for the results that the market was difficult to clear. Patients with type 2 diabetes are particularly important in the first Orforglipron test because they tend to lose weight of GLP-1 than those without state. Nevertheless, there are considerations of portfolio management. After slowing down by 2025, ELI LILLY once again discovered near the top of the market leader board thanks to the strong signs of 2025 and bidding for medical stocks. In a volatile market that can quickly erase profits, we discussed internally when we had to sell some of the stocks we picked up at $ 700 in November and January. Lilly Stock is currently trading less than $ 920. It set a record of $ 960 on August 30. We have made a decision on Wednesday, but we are tempted to sell some stocks nearly a few weeks every year to buy beaten items for the last few weeks. That kind of strategic thinking is never a sign of faith in Lilly. (The charity trust of Jim Cramer is Lly for a long time. See the full list of stocks here.) As a subscriber of CNBC Investing Club with Jim Cramer, you will receive a trading alarm before the trading of JIM. JIM sends a trading warning before buying or selling stocks in a charity trust portfolio for 45 minutes. If JIM talks about the stock of CNBC TV, wait 72 hours after issuing a transaction warning before doing a transaction. The above investment club information is subject to our terms and conditions and personal information protection policies. The receipt of the information provided in connection with the investment club does not have a trust obligation or obligation. Specific results or profits are not guaranteed.
March 28, 2024 ELI Lilly & Co. Zepbound Injection Pen.
Bloomberg | Bloomberg | Getty image
Novo Nordic I follow next Eli Lily Footprints and people are launching an online pharmacy where the company can buy weight loss drugs directly.
Despite the advantages of the first rival of the competitors, it is the latest sign of LILLY’s strong position in a favorable obesity race.
Great information shared.. really enjoyed reading this post thank you author for sharing this post .. appreciated
very informative articles or reviews at this time.
çok bilgilendirici bir yazı olmuş ellerinize sağlık teşekkür ederim
Ne zamandır web sitelerim için aradığım içeriği sonunda buldum. Bu kadar detaylı ve net açıklama için teşekkürler.